Inhibrx Biosciences, Inc.
INBXNext catalyst
Ozekibart (INBRX-109)
Unresectable or metastatic conventional chondrosarcoma
Get an email about INBX's next catalysts
Track Inhibrx Biosciences (INBX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
INBX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-2.50 | FQ end Sep/2026 | Call: tbd
FDA PDUFA Date Ozekibart (INBRX-109)
For Unresectable or metastatic conventional chondrosarcoma. BLA; no filing review issues identified. Verified against the company SEC filing on 2026-10-16.
SourceINBRX-106 Phase 2 Est. Readout
Estimated primary completion for INBRX-106 trial (NCT06353997) in Triple Negative Breast Cancer. Topline data typically follows completion by weeks to months.
SourceUpcoming FDA decisions
How INBX's past catalysts played out
Market Overview
Stock performance and key metrics
INBRX-106
Head and Neck Squamous Cell Carcinoma (HNSCC)
INBRX-109
Conventional Chondrosarcoma
INBRX-106 - Hexavalent OX40 agonist antibody
Solid Tumor
Carboplatin AUC-6
Solid Tumor
Carboplatin AUC-5
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
INBRX-106 | Phase 3 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
INBRX-109 | Phase 2 | Conventional Chondrosarcoma | - | - |
INBRX-106 - Hexavalent OX40 agonist antibody | Phase 2 | Solid Tumor | - | - |
Carboplatin AUC-6 | Phase 2 | Solid Tumor | - | - |
Carboplatin AUC-5 | Phase 2 | Solid Tumor | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Inhibrx Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Inhibrx Biosciences, Inc.'s (INBX) pipeline across Phase 3, Phase 2. Its lead program is INBRX-106 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Inhibrx Biosciences, Inc.'s next FDA catalyst?→
Inhibrx Biosciences, Inc.'s (INBX) next tracked catalyst is a PDUFA date expected Apr 14, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INBX biotech catalysts?→
Add INBX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inhibrx Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.